Skip to search formSkip to main contentSkip to account menu

gp100:209-217(210M) peptide vaccine

Known as: G9 209-2M, gp100:209-217(210M) 
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a… 
National Institutes of Health

Related topics

Related topics

6 relations
Antigen SensitizationCytotoxic T-LymphocytesMelanoma CellT-Cell Activation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines
Efforts to develop effective cancer vaccines often use combinations of immunogenic peptides to increase the applicability and… 
Highly Cited
2004
Highly Cited
2004
Phenotypic and Functional Maturation of Tumor Antigen-Reactive CD8+ T Lymphocytes in Patients Undergoing Multiple Course Peptide Vaccination
Successful immunotherapy with peptide vaccines depends on the in vivo generation of sufficient numbers of anti-tumor T cells with… 
Highly Cited
2002
Highly Cited
2002
Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1
The functional status of circulating vaccine-induced, tumor-specific T cells has been questioned to explain their paradoxical… 
Highly Cited
2000
Highly Cited
2000
Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells
Selective blunting of the status of activation of circulating tumor-specific T cells was invoked to explain their paradoxical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)